# kidney transplant rejection FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/kidney-transplant-rejection

> 6 upcoming FDA catalysts in kidney transplant rejection: tegoprubart (ELDN) on March 2029 (primary completion); tegoprubart (ELDN) on Mar to Jun 2029 (topline data readout); frexalimab (SNY) on Aug to Nov 2029 (topline data readout); frexalimab (SNY) on August 2029 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q1 2025 | [Mosdaprubart topline data readout](https://sec-api.dev/pdufa/mosdaprubart) | TNXP | kidney transplant rejection | scheduled | "The Company provided updated guidance on the timing of topline data for two of its programs: topline data for the Phase 2 study of the Company's TNX-1300 product candidate for cocaine intoxication is expected in the third quarter of 2025; and topline data for the Phase 1 study of the Company's TNX-1500 product candidate for the prevention of kidney transplant rejection is expected in the first quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937125000195/tnxp-8k_010825.htm)) |
| February 6, 2025 | [Mosdaprubart topline data readout](https://sec-api.dev/pdufa/mosdaprubart) | TNXP | kidney transplant rejection | completed, positive | "On February 6, 2025, the Company announced positive topline results from a Phase 1, single ascending dose trial of TNX-1500 in healthy participants." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937125001243/tnxp-8k_020625.htm)) |
| Q3 2025 | [TNX-1300 topline data readout](https://sec-api.dev/pdufa/tnx-1300) | TNXP | kidney transplant rejection | scheduled | "The Company provided updated guidance on the timing of topline data for two of its programs: topline data for the Phase 2 study of the Company's TNX-1300 product candidate for cocaine intoxication is expected in the third quarter of 2025; and topline data for the Phase 1 study of the Company's TNX-1500 product candidate for the prevention of kidney transplant rejection is expected in the first quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937125000195/tnxp-8k_010825.htm)) |
| September 11, 2025 | [Tegoprubart primary completion](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | completed | "NCT05983770 (Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-11 (ACTUAL); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05983770)) |
| March 2029 | [Tegoprubart primary completion](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | scheduled | "NCT07835581 (Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07835581)) |
| Mar to Jun 2029 | [Tegoprubart topline data readout](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | scheduled | "NCT07835581 (Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07835581)) |
| Aug to Nov 2029 | [Frexalimab topline data readout](https://sec-api.dev/pdufa/frexalimab) | SNY | Kidney Transplant Rejection | scheduled | "NCT07412470 (A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412470)) |
| August 2029 | [Frexalimab primary completion](https://sec-api.dev/pdufa/frexalimab) | SNY | Kidney Transplant Rejection | scheduled | "NCT07412470 (A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-15 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412470)) |
| December 2029 | [Tegoprubart primary completion](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | scheduled | "NCT06126380 (Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126380)) |
| Dec 2029 to Mar 2030 | [Tegoprubart topline data readout](https://sec-api.dev/pdufa/tegoprubart) | ELDN | Kidney Transplant Rejection | scheduled | "NCT06126380 (Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126380)) |

## Drugs

- [Mosdaprubart](https://sec-api.dev/pdufa/mosdaprubart) (TNXP)
- [TNX-1300](https://sec-api.dev/pdufa/tnx-1300) (TNXP)
- [Tegoprubart](https://sec-api.dev/pdufa/tegoprubart) (ELDN)
- [Frexalimab](https://sec-api.dev/pdufa/frexalimab) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/kidney-transplant-rejection.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "kidney transplant rejection FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/kidney-transplant-rejection

```bibtex
@misc{secapidev_indications_kidney_transplant_rejection_20261116,
  title        = {kidney transplant rejection FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/kidney-transplant-rejection}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_kidney_transplant_rejection_20261116","title":"kidney transplant rejection FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/kidney-transplant-rejection","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
